A. Bavelloni, M. Piazzi, G. Ramazzotti, R. Fiume, W. Blalock, and I. Faenza, “PI3Kα-selective inhibitor alpelisib (BYL719), may be effective as anticancer agents in Rhabdomyosarcoma”, Ital J Anat Embryol, vol. 122, no. 1, p. 21, Oct. 2017.